189 related articles for article (PubMed ID: 16461009)
1. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination.
DiPaolo N; Ni S; Gaggar A; Strauss R; Tuve S; Li ZY; Stone D; Shayakhmetov D; Kiviat N; Touré P; Sow S; Horvat B; Lieber A
Mol Ther; 2006 Apr; 13(4):756-65. PubMed ID: 16461009
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35.
Sakurai F; Nakashima K; Yamaguchi T; Ichinose T; Kawabata K; Hayakawa T; Mizuguchi H
J Control Release; 2010 Dec; 148(2):212-8. PubMed ID: 20800630
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
Ni S; Gaggar A; Di Paolo N; Li ZY; Liu Y; Strauss R; Sova P; Morihara J; Feng Q; Kiviat N; Touré P; Sow PS; Lieber A
Cancer Gene Ther; 2006 Dec; 13(12):1072-81. PubMed ID: 16874361
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.
Ni S; Bernt K; Gaggar A; Li ZY; Kiem HP; Lieber A
Hum Gene Ther; 2005 Jun; 16(6):664-77. PubMed ID: 15960598
[TBL] [Abstract][Full Text] [Related]
5. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation.
Schoggins JW; Nociari M; Philpott N; Falck-Pedersen E
J Virol; 2005 Sep; 79(18):11627-37. PubMed ID: 16140740
[TBL] [Abstract][Full Text] [Related]
6. Efficient gene delivery in human and rodent mast cells using adenovirus vectors.
Nakashima K; Sakurai F; Kawabata K; Mizuguchi H
J Control Release; 2008 Aug; 129(3):215-22. PubMed ID: 18572269
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice.
Sakurai F; Kawabata K; Koizumi N; Inoue N; Okabe M; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2006 Jul; 13(14):1118-26. PubMed ID: 16541121
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
9. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
[TBL] [Abstract][Full Text] [Related]
10. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
[TBL] [Abstract][Full Text] [Related]
11. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
[TBL] [Abstract][Full Text] [Related]
12. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.
Tatsis N; Blejer A; Lasaro MO; Hensley SE; Cun A; Tesema L; Li Y; Gao GP; Xiang ZQ; Zhou D; Wilson JM; Ertl HC
Mol Ther; 2007 Mar; 15(3):608-17. PubMed ID: 17228314
[TBL] [Abstract][Full Text] [Related]
13. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
14. CD46 represents a target for adenoviral gene therapy of malignant glioma.
Ulasov IV; Tyler MA; Zheng S; Han Y; Lesniak MS
Hum Gene Ther; 2006 May; 17(5):556-64. PubMed ID: 16716112
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors.
Hensley SE; Giles-Davis W; McCoy KC; Weninger W; Ertl HC
J Immunol; 2005 Nov; 175(9):6032-41. PubMed ID: 16237098
[TBL] [Abstract][Full Text] [Related]
16. CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy.
Camacho ZT; Turner MA; Barry MA; Weaver EA
Hum Gene Ther; 2014 Apr; 25(4):364-74. PubMed ID: 24635714
[TBL] [Abstract][Full Text] [Related]
17. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG
Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368
[TBL] [Abstract][Full Text] [Related]
18. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
[TBL] [Abstract][Full Text] [Related]
19. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
20. The subcellular location of antigen expressed by adenoviral vectors modifies adaptive immunity but not dependency on cross-presenting dendritic cells.
Henning P; Gustafsson T; Flach CF; Hua YJ; Strömbeck A; Holmgren J; Lindholm L; Yrlid U
Eur J Immunol; 2011 Aug; 41(8):2185-96. PubMed ID: 21538977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
